| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
| 02.06.02 |
Calcium-channel blockers |
|
|
Amlodipine
|
Formulary
|
Provider notes
|
|
|
Diltiazem immediate release
|
Formulary
|
Provider notes
|
|
|
Diltiazem modified release
|
Formulary
|
Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable. Provider notes - NMUH:
- Adizem-SR, Adizem-XL, Tildiem LA, Tildiem Retard available
- RFL:
- Tildiem LA, Tildiem Retard and Slozem and the preferred brands
- RNOH:
- UCLH:
- WH:
- Tildiem LA, Tildiem Retard available
|
|
|
Felodipine
|
Formulary
|
Provider notes
|
|
|
Nifedipine immediate release
|
Formulary
|
Provider notes - NMUH:
- RFL:
- RNOH:
- 10mg capsules for autonomic dysreflexia in patients with a spinal cord injury above level of T6
- UCLH:
- WH:
|
|
|
Nifedipine modified release
|
Formulary
|
Prescribe by brand name: modified-release preparations have different release characteristics and are not interchangeable. Provider notes - NMUH:
- Adalat Retard, Adalat LA, Coracten SR, Coracten XL available
- RFL:
- Adalat Retard, Adalat LA, Coracten SR and Coracten XL available
- RNOH:
- UCLH:
- WH:
- Coracten SR and Coracten XL available
- Adalat Retard (10mg and 20mg M/R tabs) discontinued
- Adalat LA out of stock until further notice
|
|
|
Nimodipine
|
 Restricted
|
Provider notes
- NMUH:
- Restricted for subarachnoid haemorrhage only
- RFL:
- Restricted for subarachnoid haemorrhage only
- RNOH:
- UCLH:
- WH:
- Nimodipine is only available for use in ischaemic neurological deficits following subarachnoid haemorrhage.
|
|
|
Verapamil
(Cardiology)
|
Formulary
|
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. Provider notes - NMUH:
- RFL:
- Verapamil injection restricted to cardiology
- Both immediate release and M/R tablets stocked
- RNOH:
- UCLH:
- WH:
|
|
|
| .... |
| Non Formulary Items |
Amlodipine + Valsartan
|
Non Formulary
|
|
|
|
Isradipine
|
Non Formulary
|
|
|
|
Lacidipine
|
Non Formulary
|
|
|
|
Lercanidipine
|
Non Formulary
|
|
|
|
Nicardipine
|
Non Formulary
|
|
|
|
| |
Key |
|
Traffic Light Status Information
| Status |
Description |
 
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|
|
